Literature DB >> 25471322

Antibody and T-cell responses associated with experimental human malaria infection or vaccination show limited relationships.

Karen M Walker1, Shinji Okitsu, David W Porter, Christopher Duncan, Mario Amacker, Gerd Pluschke, David R Cavanagh, Adrian V S Hill, Stephen M Todryk.   

Abstract

This study examined specific antibody and T-cell responses associated with experimental malaria infection or malaria vaccination, in malaria-naive human volunteers within phase I/IIa vaccine trials, with a view to investigating inter-relationships between these types of response. Malaria infection was via five bites of Plasmodium falciparum-infected mosquitoes, with individuals reaching patent infection by 11-12 days, having harboured four or five blood-stage cycles before drug clearance. Infection elicited a robust antibody response against merozoite surface protein-119 , correlating with parasite load. Classical class switching was seen from an early IgM to an IgG1-dominant response of increasing affinity. Malaria-specific T-cell responses were detected in the form of interferon-γ and interleukin-4 (IL-4) ELIspot, but their magnitude did not correlate with the magnitude of antibody or its avidity, or with parasite load. Different individuals who were immunized with a virosome vaccine comprising influenza antigens combined with P. falciparum antigens, demonstrated pre-existing interferon-γ, IL-2 and IL-5 ELIspot responses against the influenza antigens, and showed boosting of anti-influenza T-cell responses only for IL-5. The large IgG1-dominated anti-parasite responses showed limited correlation with T-cell responses for magnitude or avidity, both parameters being only negatively correlated for IL-5 secretion versus anti-apical membrane antigen-1 antibody titres. Overall, these findings suggest that cognate T-cell responses across a range of magnitudes contribute towards driving potentially effective antibody responses in infection-induced and vaccine-induced immunity against malaria, and their existence during immunization is beneficial, but magnitudes are mostly not inter-related.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; antibodies; infectious diseases; malaria

Mesh:

Substances:

Year:  2015        PMID: 25471322      PMCID: PMC4405325          DOI: 10.1111/imm.12428

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Significance of immunity against lung pathogens in untreated Parkinson's disease.

Authors:  Stephen M Todryk; William K Gray; S Rafez Ahmed; Khansaa Al-Kurkchi; Fathia G Jaat; Oliva Msuya; Richard W Walker; Diana E Jones; Catherine L Dotchin
Journal:  Parkinsonism Relat Disord       Date:  2013-10-31       Impact factor: 4.891

2.  Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites.

Authors:  Stephen L Hoffman; Lucy M L Goh; Thomas C Luke; Imogene Schneider; Thong P Le; Denise L Doolan; John Sacci; Patricia de la Vega; Megan Dowler; Chris Paul; Daniel M Gordon; Jose A Stoute; L W Preston Church; Martha Sedegah; D Gray Heppner; W Ripley Ballou; Thomas L Richie
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

3.  Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites.

Authors:  Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura
Journal:  J Infect Dis       Date:  2013-03-28       Impact factor: 5.226

Review 4.  Young lives lost as B cells falter: what we are learning about antibody responses in malaria.

Authors:  Silvia Portugal; Susan K Pierce; Peter D Crompton
Journal:  J Immunol       Date:  2013-04-01       Impact factor: 5.422

Review 5.  The link between genetic variation and variability in vaccine responses: systematic review and meta-analyses.

Authors:  Brunella Posteraro; Roberta Pastorino; Paolo Di Giannantonio; Carolina Ianuale; Rosarita Amore; Walter Ricciardi; Stefania Boccia
Journal:  Vaccine       Date:  2014-02-07       Impact factor: 3.641

6.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Authors:  Daniel P Webster; Susanna Dunachie; Jenni M Vuola; Tamara Berthoud; Sheila Keating; Stephen M Laidlaw; Samuel J McConkey; Ian Poulton; Laura Andrews; Rikke F Andersen; Philip Bejon; Geoff Butcher; Robert Sinden; Michael A Skinner; Sarah C Gilbert; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

7.  Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion.

Authors:  Joseph Illingworth; Noah S Butler; Sophie Roetynck; Jedida Mwacharo; Susan K Pierce; Philip Bejon; Peter D Crompton; Kevin Marsh; Francis M Ndungu
Journal:  J Immunol       Date:  2012-12-21       Impact factor: 5.422

8.  DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.

Authors:  Ilin Chuang; Martha Sedegah; Susan Cicatelli; Michele Spring; Mark Polhemus; Cindy Tamminga; Noelle Patterson; Melanie Guerrero; Jason W Bennett; Shannon McGrath; Harini Ganeshan; Maria Belmonte; Fouzia Farooq; Esteban Abot; Jo Glenna Banania; Jun Huang; Rhonda Newcomer; Lisa Rein; Dianne Litilit; Nancy O Richie; Chloe Wood; Jittawadee Murphy; Robert Sauerwein; Cornelus C Hermsen; Andrea J McCoy; Edwin Kamau; James Cummings; Jack Komisar; Awalludin Sutamihardja; Meng Shi; Judith E Epstein; Santina Maiolatesi; Donna Tosh; Keith Limbach; Evelina Angov; Elke Bergmann-Leitner; Joseph T Bruder; Denise L Doolan; C Richter King; Daniel Carucci; Sheetij Dutta; Lorraine Soisson; Carter Diggs; Michael R Hollingdale; Christian F Ockenhouse; Thomas L Richie
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

9.  High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria.

Authors:  Gemma Moncunill; Alfredo Mayor; Alfons Jiménez; Augusto Nhabomba; Núria Casas-Vila; Laura Puyol; Joseph J Campo; Maria Nelia Manaca; Ruth Aguilar; María-Jesús Pinazo; Mercè Almirall; Cristina Soler; José Muñoz; Azucena Bardají; Evelina Angov; Sheetij Dutta; Chetan E Chitnis; Pedro L Alonso; Joaquim Gascón; Carlota Dobaño
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Stable T-bet(+)GATA-3(+) Th1/Th2 hybrid cells arise in vivo, can develop directly from naive precursors, and limit immunopathologic inflammation.

Authors:  Michael Peine; Sebastian Rausch; Caroline Helmstetter; Anja Fröhlich; Ahmed N Hegazy; Anja A Kühl; Christoph G Grevelding; Thomas Höfer; Susanne Hartmann; Max Löhning
Journal:  PLoS Biol       Date:  2013-08-20       Impact factor: 8.029

View more
  13 in total

Review 1.  Controlled Human Malaria Infection: Applications, Advances, and Challenges.

Authors:  Danielle I Stanisic; James S McCarthy; Michael F Good
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

2.  Characterization of fine specificity of the immune response to a Plasmodium falciparum rhoptry neck protein, PfAARP.

Authors:  Aakanksha Kalra; Paushali Mukherjee; Virander S Chauhan
Journal:  Malar J       Date:  2016-09-07       Impact factor: 2.979

3.  Anti-bacterial antibody and T cell responses in bronchiectasis are differentially associated with lung colonization and disease.

Authors:  Fathia G Jaat; Sajidah F Hasan; Audrey Perry; Sharon Cookson; Santosh Murali; John D Perry; Clare V Lanyon; Anthony De Soyza; Stephen M Todryk
Journal:  Respir Res       Date:  2018-05-30

Review 4.  To B or Not to B: Understanding B Cell Responses in the Development of Malaria Infection.

Authors:  Eduardo L V Silveira; Mariana R Dominguez; Irene S Soares
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

5.  Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure.

Authors:  Victor Yman; Michael T White; Muhammad Asghar; Christopher Sundling; Klara Sondén; Simon J Draper; Faith H A Osier; Anna Färnert
Journal:  BMC Med       Date:  2019-01-30       Impact factor: 8.775

Review 6.  Contribution of Resident Memory CD8+ T Cells to Protective Immunity Against Respiratory Syncytial Virus and Their Impact on Vaccine Design.

Authors:  Angello Retamal-Díaz; Camila Covián; Gaspar A Pacheco; Angelo T Castiglione-Matamala; Susan M Bueno; Pablo A González; Alexis M Kalergis
Journal:  Pathogens       Date:  2019-09-11

7.  Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring.

Authors:  Nina Körber; Uta Behrends; Alexander Hapfelmeier; Ulrike Protzer; Tanja Bauer
Journal:  J Transl Med       Date:  2016-06-14       Impact factor: 5.531

Review 8.  How Can Elispot Add Information to Improve Knowledge on Tropical Diseases?

Authors:  Josué da Costa Lima-Junior; Fernanda Nazaré Morgado; Fátima Conceição-Silva
Journal:  Cells       Date:  2017-09-29       Impact factor: 6.600

9.  Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections.

Authors:  Lotus L van den Hoogen; Jona Walk; Tate Oulton; Isaie J Reuling; Linda Reiling; James G Beeson; Ross L Coppel; Susheel K Singh; Simon J Draper; Teun Bousema; Chris Drakeley; Robert Sauerwein; Kevin K A Tetteh
Journal:  Front Microbiol       Date:  2019-01-16       Impact factor: 5.640

Review 10.  Malaria vaccines: facing unknowns.

Authors:  Nirianne Marie Q Palacpac; Toshihiro Horii
Journal:  F1000Res       Date:  2020-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.